CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

用于乳腺癌治疗的可注射水凝胶：从肿瘤微环境响应性与主动靶向药物递送到免疫治疗与诊疗一体化

Injectable Hydrogels for Breast Cancer Therapy: From Tumor Microenvironment-Responsive and Actively Targeted Drug Delivery to Immunotherapy and Theran

调控肿瘤微环境的 CaCO3 基胶体体微反应器可普遍增强肿瘤免疫治疗

Tumor Microenvironment Modulating CaCO(3) -Based Colloidosomal Microreactors Can Generally Reinforce Cancer Immunotherapy.

抗 VEGF 治疗改善小鼠同基因胶质母细胞瘤模型中 EGFR-vIII-CAR-T 细胞的递送与疗效

Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.

放疗通过激活 NF-κB/Icam1 信号增强 EGFR 靶向 CAR-T 细胞对三阴性乳腺癌的疗效

Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling.

经工程改造识别效应沉默型肿瘤抗原靶向人 IgG1 抗体 P329G 突变 Fc 段的 CAR-T 细胞实现实体瘤的模块化靶向

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies

靶向 P329G 的 CAR-T 细胞联合含 P329G Fc 突变的人 IgG1 抗原结合抗体，在不同实体瘤模型中介导了显著的体外和体内效应功能，值得进一步推进该概念的临床转化。

肿瘤相关 Tn 和 STn 抗原：从分子机制到精准诊断与治疗

Tumor-associated Tn and STn antigens: from molecular mechanism to precision diagnosis and treatment.

Tn/STn 抗原在肿瘤发生和免疫逃逸中发挥关键作用，在诊断和治疗方面具有巨大潜力。未来研究应集中于阐明其潜在机制、开发创新检测技术，并促进多学科合作，以推动基于 Tn/STn 抗原的肿瘤分子分型、精准靶向治疗和疗效预测系统的发展，从而为癌症诊断和治疗提供新方向。

CAR-T 细胞治疗乳腺癌的进展与挑战：从分子设计到临床应用

Advances and challenges in CAR-T cell therapy for breast cancer: from molecular design to clinical application.

乳腺癌管理中的 CAR-T 细胞治疗：拓展视野并克服血液系统肿瘤之外的挑战

CAR-T cell therapy in breast cancer management: expanding horizon and overcoming challenges beyond hematologic cancers.

拓展 CAR-T 细胞与双特异性 T 细胞衔接器在实体瘤中的治疗覆盖范围

Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors.